Literature DB >> 20620970

Autoimmune complications in chronic lymphocytic leukaemia (CLL).

Clive S Zent1, Neil E Kay.   

Abstract

Patients with B-chronic lymphocytic leukaemia /small lymphocytic lymphoma (CLL) have a 5-10% risk of developing autoimmune complications, which primarily cause cytopaenia. These autoimmune cytopaenias can occur at any stage of CLL and do not have independent prognostic significance. The most common autoimmune complication is autoimmune haemolytic anaemia with a lower frequency of immune thrombocytopaenia and pure red blood cell aplasia and only rarely, autoimmune granulocytopaenia (AIG). Autoimmune cytopaenia should always be considered in the differential diagnosis of cytopaenia in patients with CLL. Patients with CLL can also have more than one form of autoimmune cytopaenia, which can occur together with bone-marrow failure. Treatment is usually effective but rarely curative for autoimmune cytopaenia complicating CLL. Optimal therapy will depend on a timely and accurate diagnosis of autoimmune cytopaenia and should be individualised according to the severity of the cytopaenia and the presence or absence of concomitant progressive CLL requiring therapy. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20620970      PMCID: PMC2909690          DOI: 10.1016/j.beha.2010.01.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  83 in total

1.  Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia.

Authors:  S H Otton; D L Turner; R Frewin; S V Davies; S A Johnson
Journal:  Br J Haematol       Date:  1999-07       Impact factor: 6.998

2.  Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease.

Authors:  G Akpek; D McAneny; L Weintraub
Journal:  Am J Hematol       Date:  1999-06       Impact factor: 10.047

3.  Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia.

Authors:  S Sallah; J Y Wan; L R Hanrahan
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

4.  Probable autoimmune neutropenia induced by fludarabine treatment for chronic lymphocytic leukaemia.

Authors:  S C Stern; S Shah; C Costello
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

5.  Symptomatic and hemopathic hemolytic anemia.

Authors:  L R WASSERMAN; D STATS; L SCHWARTZ; H FUDENBERG
Journal:  Am J Med       Date:  1955-06       Impact factor: 4.965

6.  The present status of treatment of autoimmune hemolytic anemia with ACTH and cortisone.

Authors:  W DAMESHEK; Z D KOMNINOS
Journal:  Blood       Date:  1956-07       Impact factor: 22.113

7.  CD5-negative chronic lymphocytic leukemia with indolent clinical course and autoimmune thrombocytopenia, successfully treated with rituximab.

Authors:  Masashi Okamoto; Sonoko Nakano; Kyoko Namura; Noriko Yamada; Ryo Uchida; Shin-Ichi Fuchida; Akira Okano; Naoya Ochiai; Chihiro Shimazaki
Journal:  Am J Hematol       Date:  2004-12       Impact factor: 10.047

8.  Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.

Authors:  F R Mauro; R Foa; R Cerretti; D Giannarelli; S Coluzzi; F Mandelli; G Girelli
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

9.  Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.

Authors:  J Cortes; S O'Brien; J Loscertales; H Kantarjian; F Giles; D Thomas; C Koller; M Keating
Journal:  Cancer       Date:  2001-10-15       Impact factor: 6.860

10.  Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data.

Authors:  C S Zent; M J Kyasa; R Evans; S A Schichman
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

View more
  36 in total

1.  Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.

Authors:  Yair Herishanu; Neta Goldschmidt; Osnat Bairey; Rosa Ruchlemer; Riva Fineman; Naomi Rahimi-Levene; Lev Shvidel; Tamar Tadmor; Aviv Ariel; Andrea Braester; Mika Shapiro; Erel Joffe; Aaron Polliack
Journal:  Haematologica       Date:  2015-02-06       Impact factor: 9.941

Review 2.  Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.

Authors:  Birgit Knoechel; Jens G Lohr
Journal:  J Autoimmun       Date:  2013-07-21       Impact factor: 7.094

Review 3.  A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Authors:  Mazie Tsang; Sameer A Parikh
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

4.  Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients.

Authors:  Chiara Briani; Andrea Visentin; Alessandro Salvalaggio; Silvia Imbergamo; Francesco Piazza; Mario Cacciavillani; Marta Campagnolo; Federica Frezzato; Gianpietro Semenzato; Livio Trentin
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

Review 5.  Management of chronic lymphocytic leukemia.

Authors:  Paolo Ghia; Michael Hallek
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

6.  High-resolution quantification of discrete phagocytic events by live cell time-lapse high-content microscopy imaging.

Authors:  Charles C Chu; Jonathan J Pinney; Hannah E Whitehead; Fatima Rivera-Escalera; Karl R VanDerMeid; Clive S Zent; Michael R Elliott
Journal:  J Cell Sci       Date:  2020-03-05       Impact factor: 5.285

Review 7.  Fatal Cache Valley virus meningoencephalitis associated with rituximab maintenance therapy.

Authors:  Yuanquan Yang; Jingxin Qiu; Abigail Snyder-Keller; Yongping Wu; Shufeng Sun; Haixin Sui; Amy B Dean; Laura Kramer; Francisco Hernandez-Ilizaliturri
Journal:  Am J Hematol       Date:  2018-01-25       Impact factor: 10.047

8.  Autoimmune neutropenia preceding Helicobacter pylori-negative MALT lymphoma with nodal dissemination.

Authors:  Saori Harada; Sho Yamazaki; Fumihiko Nakamura; Ken Morita; Akihide Yoshimi; Aya Shinozaki-Ushiku; Masashi Fukayama; Mineo Kurokawa
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

9.  Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims ("MedWAS").

Authors:  Eric A Engels; Ruth Parsons; Caroline Besson; Lindsay M Morton; Lindsey Enewold; Winnie Ricker; Elizabeth L Yanik; Hannah Arem; April A Austin; Ruth M Pfeiffer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-26       Impact factor: 4.254

10.  Successful treatment of acquired pure red cell aplasia with oral corticosteroids in a patient with B-cell CLL.

Authors:  Pramila Dharmshaktu; Naresh Gupta; Dinesh Kumar Dhanwal
Journal:  BMJ Case Rep       Date:  2013-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.